Mallinckrodt completes expansion of StrataGraft manufacturing facility in Madison, Wisconsin

Mallinckrodt celebrated the completion of its expanded operations and manufacturing facility for StrataGraft regenerative skin tissue in Madison, Wisconsin. The 35,000-square-foot facility provides capacity for clinical trials and commercial availability.

“The 35,000-square-foot facility provides the necessary capacity to develop and manufacture StrataGraft regenerative skin tissue for both clinical trials and commercial availability, if approved by the FDA.”prnewswire.com

• 1 source
• prnewswire.comMallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis.Mallinckrodt plcApr 24, 2019

Summarized from public sources; check the original articles before acting on it.